Search

Your search keyword '"Olivari N"' showing total 223 results
Start Over Author "Olivari N"
223 results on '"Olivari N"'

1. Adherence to the ESGE Guidelines on biliary stenting in malignant distal strictures: results from a prospective cohort study (PROTESIED) in Italy

Author

Schepis, T., additional, Zagari, R. M., additional, Crinò, S. F., additional, Sacco, M., additional, Gabbrielli, A., additional, Grassia, R., additional, Santagati, A., additional, Venezia, G., additional, Olivari, N., additional, Panarese, A., additional, Bravo, M., additional, Biviano, I., additional, Bertani, H., additional, Devani, M., additional, De Minicis, S., additional, De Roberto, G., additional, Aucello, A., additional, Pallio, S., additional, Parodi, M. C., additional, Pasquale, L., additional, Dajti, E., additional, and Tringali, A., additional

Published
2024
Full Text
View/download PDF

3. Benefits from a computer-aided detection device in colonoscopy (ACCENDO-COLO) – an interim analysis of an italian multicenter randomized clinical trial

Author

Salvi, D., additional, Pecere, S., additional, Cesaro, P., additional, Ciuffini, C., additional, Milluzzo, S. M., additional, Quadarella, A., additional, Piccirelli, S., additional, Pesatori, E. V., additional, Belluardo, N., additional, Ferrari, C., additional, Olivari, N., additional, Codazzi, M., additional, Gerardi, V., additional, Grazioli, L. Minelli, additional, Barbaro, F., additional, Papparella, L. G., additional, Petruzziello, L., additional, Costamagna, G., additional, and Spada, C., additional

Published
2023
Full Text
View/download PDF

5. OC.07.1 BENEFITS FROM A COMPUTER-AIDED DETECTION DEVICE IN COLONOSCOPY (ACCENDO-COLO) – AN INTERIM ANALYSIS OF AN ITALIAN MULTICENTER RANDOMIZED CLINICAL TRIAL

Author

Salvi, D., primary, Pecere, S., additional, Cesaro, P., additional, Ciuffini, C., additional, Milluzzo, S.M., additional, Quadarella, A., additional, Piccirelli, S., additional, Pesatori, E., additional, Belluardo, N., additional, Olivari, N., additional, Codazzi, M., additional, Minelli Grazioli, L., additional, Gerardi, V., additional, Ferrari, C., additional, Barbaro, F., additional, Papparella, L., additional, Petruzziello, L., additional, Costamagna, G., additional, and Spada, C., additional

Published
2023
Full Text
View/download PDF

11. OC.07.1 INCREMENTAL YIELD OF ARTIFICIAL INTELLIGENCE IN FOLLOWUP SCREENING COLONOSCOPIES: AN INTERIM ANALYSIS

Author

Milluzzo, S.M., primary, Cesaro, P., additional, Hassan, C., additional, Pesatori, E.V., additional, Piccirelli, S., additional, Catino, F., additional, Quadarella, A., additional, Olivari, N., additional, Minelli Grazioli, L., additional, Codazzi, M., additional, Bizzotto, A., additional, Schivardi, M.R., additional, and Spada, C., additional

Published
2021
Full Text
View/download PDF

34. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study

Author

Stroffolini T., Almasio P. L., Sagnelli E., Mele A., Gaeta G. B., Italian Hospitals' Collaborating Group, Scuteri A., Antonucci G., Iacomi F., Babudieri S., Pintus A., Stornaiuolo G., Brancaccio G., Brunetto M., Sasso R., Caporaso N., Morisco F., Chiaramonte M., Lattanzi E., Di Marco V., Venezia G., Fagiuoli S., Boninsegna S., Fattovich G., Olivari N., Ferrari C., Giuberti T., Ferrigno L., Magnani G., Massari M., Mangano C., Caserta C., Messina V., Pastore G., Palattella S., Piccinino F., Stanzione M., Pinzello G., Vinci M., Raimondo G., Caccamo G., Roffi L., Bellia V., Rizzetto M., Smedile A., Ciancio A., ANDREONE, PIETRO, Infectious and Tropical Diseases, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Gastroenterology, Università degli studi di Palermo - University of Palermo, Public,Clinical and Preventive Medicine, University of Naples Federico II, Laboratory of Epidemiology, Clinical Epidemiology Unit, Istituto Superiore di Sanita [Rome], Infectious Diseases Dept, Stroffolini T., Almasio P.L., Sagnelli E., Mele A., Gaeta G.B., Italian Hospitals' Collaborating Group, Andreone P., Scuteri A., Antonucci G., Iacomi F., Babudieri S., Pintus A., Stornaiuolo G., Brancaccio G., Brunetto M., Sasso R., Caporaso N., Morisco F., Chiaramonte M., Lattanzi E., Di Marco V., Venezia G., Fagiuoli S., Boninsegna S., Fattovich G., Olivari N., Ferrari C., Giuberti T., Ferrigno L., Magnani G., Massari M., Mangano C., Caserta C., Messina V., Pastore G., Palattella S., Piccinino F., Stanzione M., Pinzello G., Vinci M., Raimondo G., Caccamo G., Roffi L., Bellia V., Rizzetto M., Smedile A., Ciancio A., Stroffolini, T, Almasio, P, Sagnelli, E, Mele, A, Gaeta, G, Andreone, P, Scuteri, A, Antonucci, G, Iacomi, F, Babudieri, S, Pintus, A, Stornaiuolo, G, Brancaccio, G, Brunetto, M, Sasso, R, Caporaso, N, Morisco, F, Chiaramonte, M, Lattanzi, E, Di Marco, V, Venezia, G, Fagiuoli, S, Boninsegna, S, Fattovich, G, Olivari, N, Ferrari, C, Giuberti, T, Ferrigno, L, Magnani, G, Massari, M, Mangano, C, Caserta, C, Messina, V, Pastore, G, Palattella, S, Piccinino, F, Stanzione, M, Pinzello, G, Vinci, M, Raimondo, G, Caccamo, G, Roffi, L, Bellia, V, Rizzetto, M, Smedile, A, and Ciancio, A

Subjects
Male, HBsAg, viruses, HIV Infections, Antibodies, Viral, HBeAg, Hepatitis, Liver disease, CHRONIC HEPATITIS B, epidemiology, GEOGRAPHICAL LANDSCAPE, 0302 clinical medicine, 80 and over, Prevalence, Viral, Chronic, Aged, 80 and over, 0303 health sciences, Geography, Age Factors, virus diseases, Hepatitis C, Hepatitis B, Middle Aged, Hepatitis D, 3. Good health, Infectious Diseases, Cirrhosis, Italy, Medicine, 030211 gastroenterology & hepatology, Female, Hepatitis D virus, Human, Adult, Hepatitis, Viral, Human, Adolescent, Antibodies, 03 medical and health sciences, Hepatitis B, Chronic, HDV, Virology, Cirrhosis, HBeAg, HDV, Hepatitis B, Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Antibodies, Viral, Cross-Sectional Studies, Female, Geography, HIV, HIV Infections, Hepatitis B, Chronic, Hepatitis, Viral, Human, Humans, Italy, Male, Middle Aged, Prevalence, Virology, Infectious Diseases, medicine, Aged, Cross-Sectional Studies, HIV, Humans, 030304 developmental biology, Cirrhosi, business.industry, medicine.disease, digestive system diseases, business
Abstract

The aim of the study was to evaluate the characteristics of chronic hepatitis B with special reference to the geographical origin of the patients and to the prevalence of HBeAg and viral and non-viral co-factors of liver disease. A cross-sectional multicenter survey was undertaken, which enrolled 1,386 HBsAg chronic carriers observed consecutively in 21 referral centers over a 6-month period. The prevalence of HBeAg in patients was 11%; the presence of HBeAg was associated independently with a younger age and co-infection with HIV. Anti-HDV, anti-HCV, or anti-HIV antibodies were detected in 8.1%, 6.5%, and 2%, respectively. However, among the patients first diagnosed during the study period (incident cases), 14.3% were anti-HDV positive. Seven percent of the patients were immigrants; they were younger than Italian patients and 18% were HBeAg positive; no difference was observed in the prevalence of anti-HDV, anti-HCV, or anti-HIV antibodies. The presence of cirrhosis was associated independently with an age >52 years, the presence of anti-HDV or anti-HCV, alcohol use >4 drinks/day, and a high BMI. The clinical epidemiology of chronic hepatitis B virus (HBV) infection shows a dynamic profile, with the potential for re-emergence of cases with HBeAg or anti-HDV and an emerging impact of metabolic factors on the evolution of liver disease.

Published
2009

37. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

Author

Pegbeliver, Study Group, Colombo, M, Facchetti, F, Massetto, B, Regep, L, Iannacone, C, Giuberti, T, Fargion, S, Farci, P, Boninsegna, S, Di Marco, V, Fasano, M, Sagnelli, E, Di Costanzo, Gg, Viganò, M, Lampertico, P, Andreone, P, Riili, A, Scuteri, A, Cursaro, C, Andriulli, A, Niro, Ga, Angarano, G, Santantonio, Ta, Palattella, Ms, Brunetto, MAURIZIA ROSSANA, Colombatto, P, Coco, B, Ciccorossi, P, Oliveri, F, Sacco, R, Bruno, S, Bollani, S, Chiesa, A, Carosi, G, Baiguera, C, Rossi, S, Zaltron, S, Puoti, M, Cozzolongo, R, Giannuzzi, V, Craxì, A, Calvaruso, V, Venezia, G, Lanza, Ag, Di Perri, G, Cariti, G, Mollaretti, O, De Blasi, T, Kulmiye, C, Rostagno, R, Lai, Me, Serra, G, Chessa, L, Balestrieri, C, Cauli, C, Fargion, Sr, Bertelli, C, Fatta, E, Fattovich, G, Pasino, M, Zanni, S, Olivari, N, Zagni, I, Ferrari, C, Schivazappa, S, Laccabue, D, Penna, A, Gaeta, G, Stanzione, M, Stornaiuolo, G, Martines, D, Raimondo, G, Caccamo, G, Squadrito, G, Isgrò, G, Rizzetto, M, Lagget, M, Carenzi, S, Ruggiero, G, Marrone, A, Messina, V, Di Caprio, Du, Selva, V, Toniutto, P., Lampertico, P, Viganò, M, Di Costanzo, GG, Sagnelli, E, Fasano, M, Di Marco, V, Boninsegna, S, Farci, P, Fargion, S, Giuberti, T, Iannacone, C, Regep, L, Massetto, B, Facchetti, F, Colombo, M, and Calvaruso, V

Subjects
Adult, Male, HBsAg, medicine.medical_specialty, Hepatitis B virus, Time Factors, Anti-HIV Agents, medicine.disease_cause, Gastroenterology, Antiviral Agents, Group B, law.invention, Polyethylene Glycols, Pharmacotherapy, Hepatitis B, Chronic, Randomized controlled trial, law, Pegylated interferon, Internal medicine, medicine, Humans, Hepatitis B e Antigens, business.industry, Lamivudine, Interferon-alpha, Alanine Transaminase, Hepatitis B, Middle Aged, medicine.disease, Recombinant Proteins, Treatment Outcome, Immunology, DNA, Viral, Interferon, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisation plus HBV DNA3400 IU/ml (primary), HBV DNA2000 IU/ml and HBsAg clearance at 48 weeks after treatment.Forty-eight weeks after treatment, six patients in group A and 13 in group B achieved alanine aminotransferase normalisation plus HBV DNA3400 IU/ml (11.8% vs 25.0%, p=0.08), 6 vs 15 patients had HBV DNA2000 IU/ml (11.8% vs 28.8%, p=0.03), 0 vs 3 achieved HBsAg clearance (0% vs 5.8%, p=0.24) and 0 vs 5 had HBsAg10 IU/ml (0% vs 9.6%, p=0.06). While extended PegIFN treatment was the strongest independent predictor of response, the combination with lamivudine did not improve responses. Discontinuation rates were similar among the groups (19.6%, 23.1%, 32.0%, p=0.81) and were mostly due to PegIFN-related adverse events.In HBeAg-negative genotype D patients with chronic hepatitis B, PegIFN treatment for 96 weeks was well tolerated and the post-treatment virological response improved significantly compared with 48 weeks of treatment.http://ClinicalTrials.gov registration number: NCT01095835.

Published
2013

38. Hernia repair in the Lombardy region in 2000: preliminary results

Author

Ferrante, F., Rusconi, A., Galimberti, A., Grassi, M., Beluffi, L., Salamina, G., Casati, A., Cassinelli, G. B., Colpani, L., Colledan, M., Forloni, B., Geroni, P., Longoni, M., Morelli, A., Novelino, L., ENRICO OPOCHER, Pecis, C., Perrone, G., Baroni, C., Capretti, P. L., Cazzaniga, R., Giovannetti, M., Puccio, F., Marcianò, P., Sbarbada, V., Scheda Ricciotti, G., Tambussi, U., Zola, C., Formenti, A., Rumi, A., Savio, S., Tommasini Degna, C., Alquati, P., Brown, P., Gafà, M., Martinotti, A., Costa, M., Confalonieri, G. M., Crema, G., Erba, R., Frega, G., Olivari, N., Pricolo, R., Benati, L., Campo, S., Mariani, G., Bruni, T., Fontanili, M., Arisi, G. P., Beltramo, M., Bocca, M., Bragherio, G., Brambilla, A., Cacioli, D., Calzoni, D., Magnoni, E., Castoldi, M., Ceriani, V., Ballabio, R., Confalonieri, F., Contessini Avesani, E., Campanelli, G. P., Trivellini, G., Corsi, C., Croce, E., Creperio, G., Di Carlo, V., Familiari, G., Ferla, F., Ferrari, G., Forti, D., Greco, D., Fox, U., Gherardi, G., Lunghi, C., Maggioni, P., Mantovani, G., Maruotti, R., Mascia, G., Mentasti, A., Mezzeti, M., Monestiroli, U., Nespoli, A., Potestio, M., Rolandi, P., Rosati, R., Roviaro, G. C., Sampietro, R., Scorza, R., Staudacher, C., Stefanoni, G., Taschieri, A., Tenchini, P., Trabattoni, P., Trabucchi, E., Uggeri, F., Bottani, G., Cebrelli, C., Fossati, G., Ferrante, F, Rusconi, A, Galimberti, A, Grassi, M, Beluffi, L, Salamina, G, Casati, A, Cassinelli, G, Colpani, L, Colledan, M, Forloni, B, Geroni, P, Longoni, M, Morelli, A, Novelino, L, Opocher, E, Pecis, C, Perrone, G, Baroni, C, Capretti, P, Cazzaniga, R, Giovannetti, M, Puccio, F, Marciano, P, Sbarbada, V, Scheda Ricciotti, G, Tambussi, U, Zola, C, Formenti, A, Rumi, A, Savio, S, Tommasini Degna, C, Alquati, P, Brown, P, Gafa, M, Martinotti, A, Costa, M, Confalonieri, G, Crema, G, Erba, R, Frega, G, Olivari, N, Pricolo, R, Benati, L, Campo, S, Mariani, G, Bruni, T, Fontanili, M, Arisi, G, Beltramo, M, Bocca, M, Bragherio, G, Brambilla, A, Cacioli, D, Calzoni, D, Magnoni, E, Castoldi, M, Ceriani, V, Ballabio, R, Confalonieri, F, Contessini Avesani, E, Campanelli, G, Trivellini, G, Corsi, C, Croce, E, Creperio, G, Di Carlo, V, Familiari, G, Ferla, F, Ferrari, G, Forti, D, Greco, D, Fox, U, Gherardi, G, Lunghi, C, Maggioni, P, Mantovani, G, Maruotti, R, Mascia, G, Mentasti, A, Mezzeti, M, Monestiroli, U, Nespoli, A, Potestio, M, Rolandi, P, Rosati, R, Roviaro, G, Sampietro, R, Scorza, R, Staudacher, C, Stefanoni, G, Taschieri, A, Tenchini, P, Trabattoni, P, Trabucchi, E, Uggeri, F, Bottani, G, Cebrelli, C, and Fossati, G

Subjects
Male, Reoperation, medicine.medical_specialty, Hernia, medicine.medical_treatment, Risk Assessment, Severity of Illness Index, Postoperative Complications, Recurrence, Surveys and Questionnaires, medicine, Humans, Anesthesia, Herniorrhaphy, Surgical repair, Mesh, Recurrent Inguinal Hernia, Hospital stay, Laparotomy, Surgical approach, business.industry, General surgery, Surgical Mesh, medicine.disease, Hernia repair, Surgery, Treatment Outcome, Female, Follow-Up Studies, Health Care Surveys, Italy, Laparoscopy, Anterior approach, business, Abdominal surgery
Abstract

Hernia repair is the most common surgical procedure in general surgery in Italy and in the Lombardy region. In the last decade, the use of mesh, the concept of a tension-free technique, and the postoperative rate of recurrences after Bassini or Shouldice operations have completely changed the surgical approach to hernia repair. For this reason, we sent a questionnaire to 148 surgical departments in the Lombardy region to investigate about total hernia operations performed in 2000 in Lombardy, the surgical approach, the surgical techniques used, the type of anesthesia and the hospital stay. One hundred five out of 148 surgical departments returned the questionnaire, and we collected information on a total of 16,935 surgical operations for hernia: 16,494 were performed using tension-free techniques. The inguinal anterior approach is the one of choice for primary and recurrent inguinal hernia, whereas the open preperitoneal and laparoscopic approaches are limited to bilateral and recurrent hernias. The majority of cases were treated under locoregional anesthesia and with a hospital stay of two nights.

Published
2002

40. Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice

Author

Salerno, F., Cazzaniga, M., Merli, M., Spinzi, G., Saibeni, S., Salmi, A., Fagiuoli, S., Spadaccini, A., Trotta, E., Laffi, G., Koch, M., Riggio, O., Boccia, S., Felder, M., Balzani, S., Bruno, S., Angeli, P., Gobbo, G., Monti, V., Ridola, L., Terreni, N., Facciotto, C., Olivari, N., Gaffuri, G., Russo, L., Gatta, A., Romanelli, R. G., Marra, F., Moretti, A., Mangone, M., Gullini, S., Chilovi, F., Casetti, T., Okolicsanyi, L., Alimonti, P., Pazzi, P., Salvagnini, M., Colli, A., Andreoletti, M., Leo, P., Bellis, L., Lorenzini, I., Salerno, F, Cazzaniga, M, Merli, M, Spinzi, G, Saibeni, S, Salmi, A, Fagiuoli, S, Spadaccini, A, Trotta, E, Laffi, G, Koch, M, Riggio, O, Boccia, S, Felder, M, Balzani, S, Bruno, S, and Angeli, P

Subjects
Male, medicine.medical_specialty, kidney, ascites, hepatorenal syndrome, liver cirrhosis, midodrine, portal hypertension, terlipressin, Midodrine, Cohort Studies, Spontaneous bacterial peritonitis, Hepatorenal syndrome, Albumins, Internal medicine, Ascites, Prevalence, medicine, Humans, Vasoconstrictor Agents, Prospective Studies, Prospective cohort study, Aged, Hepatology, business.industry, Mortality rate, Middle Aged, medicine.disease, Surgery, Treatment Outcome, Italy, Ascite, Female, Liver function, medicine.symptom, business, Terlipressin, medicine.drug
Abstract

Background & Aims: Hepatorenal syndrome (HRS) is a severe complication of cirrhosis with ascites. The International Ascites Club recommended strict diagnostic criteria and treatment with vasoconstrictors and albumin. Aim of this prospective cohort study was to investigate the prevalence of HRS, diagnostic criteria, treatment and 3-month outcome in the daily-clinical-practice. Methods: Two-hundred-fifty-three patients with cirrhosis and renal failure consecutively admitted to 21 Italian hospitals were recruited. Results: The prevalence of HRS was 45.8% (30% type-1 and 15.8% type-2). In 36% of cases HRS was presumed because not all diagnostic criteria could be fulfilled. In 8% of cases HRS was superimposed on an organic nephropathy. Patients with HRS type-1 were younger and showed higher leukocyte count, higher respiratory rates, and worse liver function scores. Sixty-four patients with HRS type-1 received vasoconstrictors (40 terlipressin and 24 midodrine/octreotide). A complete response was obtained in 19 cases (30%) and a partial response in 13 (20%). Age was the only independent predictor of response (p = 0.033). Three-month survival of patients with HRS type-1 was 19.7%. Survival was better in patients who responded to therapy. Age (p = 0.017), bilirubin (p = 0.012), and creatinine increase after diagnostic volume expansion (p = 0.02) independently predicted death. The mortality rate was 97% among patients with at least two negative predictors. Conclusions: The diagnostic criteria of HRS in our daily-clinical-practice could not be completely fulfilled in one third of cases. The treatment with vasoconstrictors and albumin was widely implemented. Mortality was strongly predicted by simple baseline variables.

Published
2011

41. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian Study

Author

Stroffolini, T, Almasio, P, Sagnelli, E, Mele, A, Gaeta, Gb, Andreone, P, Scuteri, A, Antonucci, G, Iacomi, F, Babudieri, S, Pintus, A, Stornaiuolo, G, Brancaccio, G, Brunetto, M, Sasso, R, Caporaso, N, Morisco, F, Chiaramonte, M, Lattanti, E, Di Marco, V, Venezia, G, Fagiuoli, S, Boninsegna, S, Fattovich, Giovanna, Olivari, N, Ferrari, C, Giuberti, T, Ferrigno, L, Magnani, G, Massari, M, Mangano, C, Caserta, C, Messina, V, Pastore, G, Palatella, S, Piccinino F, Stanzione M, Pinzello, G, Vinci, M, Raimondo, G, Cacciamo, G, Roffi, L, Bellia, C, Rizzetto, M, Smedile, A, and Ciancio, A.

Subjects
Italy, hepatiits B virus, chronic hepatitis, clinical epidemiology
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results